Case 20- Pharmacology 2 Flashcards
Newer anticoagulants (NOACs)
NOACs interrupt part of the coagulation cascade and are as effective as warfarin. The main difference are that NOACs are less influenced by diet and other medication so don’t require frequent blood tests and monitoring.
Direct thrombin inhibitors
Parenteral forms
• Hirudins- polypeptides which act as direct thrombin inhibitors
• Lepirudin- recombinant hirudin that binds irreversibly to both fibrin binding and catalytic sites on thrombin and is used for thromboembolic disease in patients with type II HIIT
• Other example Bivaliruding and argatroban
Orally active direct thrombin inhibitors= Dabigatran
Direct inhibitors of factor XA- Rivaroxaban, Apixaban, Edoxaban
- Only oral dosage forms. They directly bind to and inhibit both free and bound factor Xa.
- They are administered orally for prevention of venous thromboembolism following hip or knee surgery and prevention of stroke in patients with atrial fibrillation.
- Has a rapid onset of action and a shorter half life than warfarin.
- It is metabolised in the liver but can be used in liver disease if there is no coagulopathy. Renal excretion is minimal
- Does not require routine oral anticoagulant monitoring.
- The Antidote is Andexanet alfa or Prothrombin complex concentrate (PCC
Direct thrombin (factor IIa) inhibitors- i.e. dabigatran (oral), bivalirudin and argatroban (parenteral)
- Competitive reversible inhibitor of thrombin
- Used for prophylaxis of venous thromboembolism after hip or knee replacement surgery. Treatment for DVT and PE. Prevention of stroke and embolism in patients with atrial fibrillation
- Has a rapid onset of action, given on a fixed dose
- Does not require routine oral anticoagulant monitoring
- Avoid in severe hepatic impairment and if CrCl <30ml/min
- Antidote- Idarucizumab
Use of Antiplatelet drugs
Platelets provide the initial haemostatic plug at sites of vascular injury. Inhibition of platelet function is a useful prophylactic and therapeutic strategy against MI and stroke caused by thrombosis.
What triggers platelet aggregation
Prostaglandins, TXA2 (Thromboxin A2), ADP, thrombin and fibrin
Substances which increase intracellular cAMP inhibit platelet aggregation
cAMP, prostacyclin (PGI), adenosine. Adenosine acts through adenosine A2 receptors to increase platelet cAMP and inhibit aggregation.
Anti-platelet drugs examples
- COX inhibitor (inhibits PG and TXA)- Aspirin
- ADP receptor pathway inhibitor- Ticlopidine, Clopidogrel
- Glycoprotein IIb/IIIa inhibitors- Abciximab, Tirofiban and Eptifibatide
- Phosphodiesterase inhibitor (increase cAMP)- Dipyridamole, Cilostazol
Platelet derived thromboxane A2 (TXA2) promotes aggregation
Anti-platelet drugs i.e. Aspirin
- Aspirin irreversibly inhibits COX-1 therefore inhibiting the synthesis of TXA2
- Because platelets do not contain DNA or RNA they cannot synthesise new COX-1
- The inhibition is irreversible and is effective for the life of the circulation platelet (7-10 days)
- Clinical use- used prophylactically to prevent arterial thrombosis leading to transient ischaemic attack, stroke and myocardial infarction
What happens when an atherosclerotic plaque ruptures
It stimulates platelets to bind to it which release cytokines stimulating the synthesis of thromboxin and stimulates expression of Glycoprotein IIa/IIIb receptors which platelets bind to each other with.
Abciximab
A monoclonal antibody to receptors for glycoprotein IIb/IIIa
Fibrinolytic (thrombolytic) drugs i.e. streptokinase, alteplase
- Thromboses are dynamic- there is balance between break down (fibrinolysis) and formation
- Thrombolytic drugs potential the effects of the fibrinolytic system
- MoA: they activate conversion of plasminogen to plasmin which breaks down fibrin thus dissolving the clot
- Endogenous forms of plasminogen activator- Alteplase
- Protein synthesised by Streptococci which is Streptokinase
- Derived from neonatal kidney cells- Urokinase
- Administered IV- immediate
- Short half life
- Main hazard is bleeding such as cerebral haemorrhage
Clinical use Fibrinolytic drugs
Restoring catheter and shunt function by lysing clots causing occlusion. They are principally used to reopen occluded arteries in patients with stoke or acute myocardial infarction
Clinical use of Anticoagulants and Antiplatelet agents
Anticoagulants are principally indicated for the prevention of recurrent thrombosis in patients with venous thromboembolism (VTE), which includes deep venous thrombosis and pulmonary embolism, and ischemic stroke.
Antiplatelet agents are used prophylactically to prevent arterial thrombosis leading to transient ischemic attack, stroke, and myocardial infarction
Stroke imaging process
- Assess history- for example, are they in the thrombolysis window/ PMH
- Non contrast CT head and/or intracranial CT angiogram- to assess for intracranial haemorrhage
- MRI head or angiopathy- for clarification, angiopathy to remove a clot
Attenuation on CT
High attenuation on CT= Hyperdense, white. For example, bone and acute haemorrhage
Low attenuation on CT= Hypodense, black. For example, CSF, water, air
Isodense on CT- Grey, same colour as surrounding brain parenchyma- reference density